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Clinical consequences of hypomagnesemia are manifold and include various
neurological syndromes up to life-threatening conditions. Despite its importance,
magnesium is generally not routinely determined leading to an under-recognition of
hypomagnesemia-related disorders. In the past years, there are growing numbers of
reports of hypomagnesemia-induced cerebellar syndromes (HiCS) with corresponding
cerebellar edema, which might be a distinct disease entity. To provide further insights
into HiCS, we describe a patient with HiCS and performed a literature review on
cerebellar syndromes due to severe hypomagnesemia with regard to the clinical, MRI,
and laboratory findings. We identified 17 cases, so including our case, 18 cases
contribute to this review. Summarized, HiCS seems to be a distinct disease entity
because of the remarkable similarities of clinical, MRI, and laboratory features. It should
be diagnosed and treated early to avoid recurrent disease courses, residual symptoms,
and potentially life-threatening conditions such as seizures. Physicians must be alert to
HiCS as magnesium is usually not part of the routine electrolyte panel.
Keywords: cerebellar syndrome, hypomagnesemia, oedema, MRI, literature review, recurrent disease, ataxia
INTRODUCTION
Magnesium (Mg) plays an important role in many biochemical and physiological processes
particularly in the brain, heart, and skeletal muscle (1). Being the second most abundant
intracellular cation after potassium, it is involved in over 600 enzymatic reactions including energy
metabolism, protein synthesis, stabilizing vascular endothelium, and regulating neurotransmitter
function (1, 2). As an essential ion to the human body, Mg hemostasis is strictly regulated by the
uptake in the small intestine and the excretion in the kidney.
Clinical consequences of hypomagnesemia are manifold and include electrolyte abnormalities
(hypokalemia, hypocalcemia), arrhythmias (ventricular arrhythmias, torsade de pointes,
supraventricular tachycardia), and various neurological syndromes such as carpopedal spasm,
muscle cramps, muscle fasciculations, myopathy, vertigo, nystagmus, choreoathetosis, hemiparesis,
depression, delirium, and seizures (1, 2). Despite its importance, serumMg values are generally not
routinely determined leading to an under-recognition of hypomagnesemia-related disorders (2).
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In recent years, there is a growing number of reports
of hypomagnesemia-induced cerebellar syndromes with
corresponding cerebellar edema seen on MRI which might be a
distinct disease entity (3–17).
We describe a 74-year-old man with recurrent cerebellar
syndrome due to hypomagnesemia with regard to the clinical
course, laboratory analysis, and MRI characteristics. Also,
we performed a literature review on cerebellar syndromes
due to severe hypomagnesemia to provide insights into this
pathologic entity.
CASE DESCRIPTION
First Episode 2015
In July 2015, a 71-year-old man was admitted to the hospital due
to vertigo, walking difficulties, dysarthria, nausea, and vomiting
for 3 weeks. A brain MRI 2 weeks before admission was
normal. On admission, the patient was fully orientated with a
normal afebrile general condition (blood pressure 120/81mmHg,
pulse 86/min). The neurological examination revealed severe
dysarthria and gait ataxia (walking only with support).
Pre-existing conditions were type 2 diabetes mellitus,
hypertension, hyperlipidemia, intermittent hypokalemia,
vitamin B12 deficiency, monoclonal gammopathy (MGUS),
and small-fiber polyneuropathy with secondary restless
legs syndrome (Table 1). Consequently, the patient was
on the following medications: esomeprazole, rosuvastatin,
acetylsalicylic acid, pramipexole, lorazepam, solifenacin,
sitagliptin/metformin, potassium chloride, and metoclopramid.
Brain MRI was repeated revealing bilateral cerebellar edema
that was interpreted as subacute stroke leading to a stroke
work-up including transthoracic echocardiography, trans- and
extracranial Doppler ultrasound and long-term ECG without
pathological findings (Figure 1, Table 2). In addition, deficiency
of folic acid and vitamin D and dyselectrolytemia (Table 3) were
diagnosed, and calcium, folic acid, Mg (10 mmol per day), and
vitamin D were supplemented orally. Importantly, Mg (10 mmol
per day orally) was continuously taken from now on.
Because of persistent symptoms, the patient was transferred
to a neurorehabilitation ward. The diagnosis of stroke was
questioned and cerebellitis was suspected. Therefore, a
spinal MRI, extensive blood examinations with regard to
paraneoplastic, autoimmune, and infectious diseases (anti-
amphiphysin, anti-CV2, anti-PNMA2, anti-Ri, anti-Yo, anti-Hu,
anti-recoverin, anti-SOX1, anti-Titin, anti-GAD, anti-NMDA,
anti-VGCC, anti-LGi1, anti-CASPR2, GQ1b, anti-MAG,
acetylcholine-receptor-antibodies, ANA, anti-dsDNA, anti-
TPO, HIV, syphilis, lyme borreliosis, HHV6, herpes simplex,
cytomegalovirus, vitamin B12, toxoplasmosis, herpes zoster,
enterovirus, influenza) as well as an abdominal ultrasonography
was performed and found to be normal. The cerebrospinal
fluid (CSF) analysis were normal (including FACS analysis
and cytology) except for an elevated protein of 0.7 g/L and
mirrored oligoclonal bands (OCBs) attributed to the already
known MGUS. There was a steady improvement of symptoms
under continuous Mg, calcium, folic acid, and vitamin D
supplementation, and after 5 months, the only patient’s
complaint was about rare movement-associated vertigo for a
few seconds. The then performed neurological examination and
brain MRI were normal.
Second Episode 2017
In July 2017, the patient was hospitalized due to vertigo, nausea,
vomiting, and inability to walk for the past 3 days. Medication
was unchanged and especially oral Mg substitution (10 mmol
daily) was continuously taken since 2015. The neurological
examination showed saccadic eye movements, bilateral intention
tremor of the arms, and severe gait ataxia.
Brain MRI revealed recurrent edema in the left cerebellar
hemisphere. Recurrent cerebellitis was suspected and most
examinations that were performed during the first episode in
2015 were repeated including the extensive blood examinations
as described earlier and a CSF analysis, but reported to be
normal despite the known elevated protein and mirrored OCBs
in the CSF. In addition, FDG-PET and dermatological and
urological examination for tumor screening were negative.
Laboratory examination showed slight dyselectrolytemia that
was orally substituted; Mg was not controlled (Table 3). Pulse
therapy with glucocorticoids (1,000mg methylprednisolone
for 3 days) with oral tapering off was administered with clear
clinical improvement supporting the diagnosis of cerebellitis.
Neurorehabilitation was performed with further clinical
improvement and eventually the patient only complained
about residual vertigo when turning around and intermittent
nausea. The neurological examination showed a pathologic
vestibulo-ocular reflex suppression, mild bilateral ataxia in the
finger-to-nose test (FNT), and impaired tandem walking. There
was no relevant impact on activities of daily living. Medication
was continued unchanged.
Third Episode 2019
In September 2019, the patient was again hospitalized due
to progressive walking difficulties leading to an inability to
walk. Medication was again unchanged and especially oral Mg
substitution (10 mmol daily) was continuously taken since
2017. Neurological examination showed first-degree nystagmus,
bilateral intention tremor in the FNT, and severe gait ataxia.
Brain MRI showed unchanged hyperintensities in the left
cerebellum. Recurrent cerebellitis was suspected and blood
examinations with regard to paraneoplastic and infectious
diseases (borreliosis, syphilis, anti-amphiphysin, anti-CV2, anti-
PNMA2, anti-Ri, anti-Yo, anti-Hu, anti-recoverin, anti-SOX1,
anti-Titin), a CSF analysis, and a spinal MRI were repeated
and normal or without new information. In addition, a
thoraco-abdominal CT, Aquaporin-4 antibodies, and anti-
MOG antibodies were performed and normal. Glucocorticoid
pulse therapy resulted in an improvement of limb ataxia
with persisting gait ataxia. In the following month, including
neurorehabilitative measures, there was an improvement of
symptoms, and in February 2020, there was only residual
vertigo during turning movements and intermittent nausea.
Brain MRI was unchanged. Laboratory examinations showed
persistent dyselectrolytemia including severe hypomagnesemia
<0.1 mmol/l, severe hypocalcemia, and hypokalemia (Table 3)
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TABLE 1 | Clinical summery of reported cases.
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Case
report
71 m Subacute vertigo,
dysarthria, nausea,
impaired walking
Dysarthria, gait ataxia HT, T2DM, PNP, RLS,
MGUS dyslipidemia
PPI Mg p.o.
PPI stop
y y Vertigo, nausea
(3) 57 m Subacute dysarthria,
gait ataxia
Dysarthria, nystagmus,
ataxia, cognitive
impairment, HT
Alcohol abuse,
pancreatitis, liver
steatosis, seizure
Alcohol abuse +
withdrawal
Mg i.v. y n Dysarthria,
nystagmus, gait
ataxia
(4) 59 m Sudden-onset vertigo,
nausea, tinnitus, falls
Intermittent DBN,
ataxia, somnolence,
seizures, arrhythmia
HT, T2DM, ulcerative
colitis, ileostomy
Intestinal
malabsorption
Mg + Ca i.v. y n
(5) 49 m Subacute
nausea/vomiting,
diplopia, headache
Nystagmus,
tachycardia,
somnolence, ataxia,
hydrocephalus, HT
Alcohol abuse, HT,
hyperlipidemia, GERD
PPI, alcohol abuse Mg i.v. y y Mild ataxia left
hand
(5) 60 m Vertigo, oscillopsia,
vomiting, unsteadiness
DBN, limb ataxia, gait
ataxia
Alcohol abuse, T2DM,
HT, stroke
PPI Mg i.v.
PPI stop
y n Broad-based gait
(5) 80 w Seizure, dizziness,
vomiting
DBN, ataxia HT, Parkinson’s
disease, systemic
sclerosis, GERD
PPI Mg y n Dizziness,
nystagmus
(6) 38 m Dizziness, gait ataxia,
oscillopsia
DBN, limb/gait ataxia
dysdiadokinesia
HT PPI Mg i.v.
PPI stop
y y
(7) 68 w Vertigo, visual blurring,
nausea/vomiting
Periodic DBN, seizures
dysmetria, somnolence
Scleroderma, diarrhea,
vomiting, weight loss
Small intestine
resection
Mg i.v., Ca,
Po
y n No
(8) 43 m Dysarthria, ataxia,
nausea, headache,
mental disorder
Confusion, delirium,
dysarthria,
hyperreflexia, ataxia
T2DM, smoking PPI Mg + Ca i.v.
PPI stop
y n Cognition, ataxia
(9) 72 m Progressive dysarthria,
ataxia, headache
Nystagmus dysarthria,
dysphagia, dysmetria,
gait ataxia
Sigmoid carcinoma,
metastases, weight
loss, colon resection
PPI, short bowel
syndrome
Mg y n No
(10) 73 w Nausea, dizziness,
lethargy, confusion
Cerebellar syndrome,
seizure, arrhythmia
T2DM, weight loss,
hyperlipidemia, HT
PPI Mg i.v. y
(11) 68 w Vertigo, nausea, seizure DBN, cerebellar
syndrome
HT, cholecystectomy Unknown Mg i.v. y y Nystagmus, gait
ataxia
(12) 32 m Left side weakness,
imbalance
Dysarthria,
hypoesthesia, limb/gait
ataxia, hemiparesis
Connective tissue
disease
Gitelman
syndrome
Mg + K p.o. y n
(13) 74 Subacute slurred
speech, impaired gait,
irritability, diarrhea
Nystagmus, dysarthria,
dysmetria, gait ataxia
HT, hyperlipidemia,
seizure
PPI, diarrhea Mg + Ca i.v.
PPI stop
y n No
(14) 60 m Thoracic discomfort,
vertigo, nausea, ataxia
Ataxia, tremor,
dysarthria, nystagmus,
impaired walking
Alcohol abuse, HT,
coronary artery
disease, diarrhea
PPI Mg, Ca p.o. y y Could walk and
eat
(15) 42 m Anorexia, nausea,
headache, dizziness
PPI PPI stop y n No
(16) 61 w Weakness, gait
impairment, cognitive
impairment
Nystagmus, dysmetria,
gait ataxia, kinetic
tremor, confusion
Obesity, HT, T2DM,
obstructive sleep
apnea
TRPM6 mutation Mg i.v. y
(17) 41 m Subacute dysarthria,
oscillopsia, paresthesia,
limb tremor
Dysarthria, head
tremor, ataxia,
confusion
T2DM, HT, GERD,
weight loss, diarrhea
PPI Mg i.v. y y No
Ref, references; y, years; m, male; f, female; i.v., intravenously; p.o., orally; Mg, magnesium; Ca, calcium; K, potassium; PPI, proton pump inhibitor; RLS, restless legs syndrome; DBN,
downbeat nystagmus; HT, hypertension; T2DM, type 2 diabetes mellitus; MGUS, monoclonal gammopathy; GERD, gastroesophageal reflux disease; PNP, polyneuropathy; y, yes; n, no.
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FIGURE 1 | Brain MRI findings. First episode: Images (A–E); second episodes (F–J) (resembling residual findings on further follow up MRIs): (A+F):
T2-weighted-images (T2W); (B+G): fluid-attenuated inversion recovery (FLAIR) images; (C+H): diffusion-weighted images (DWI); (D+I): apparent diffusion coefficient
(ADC) images; (E+J): T1-weighted images (T1W) with gadolinium (Gd). Images show left-dominant cerebellar hyperintense lesions on T2W, FLAIR, and ADC images
that are hypointense without Gd enhancement T1W images. DWI images at first episode showed hyperintense lesion and were normal at second episode.
leading to the diagnosis of hypomagnesemia-induced cerebellar
syndrome (HiCS).
In an endocrinological work-up, the patient denied regular
consumption of alcohol or use of diuretics. He had no
gastrointestinal symptoms (i.e., diarrhea or vomiting) and
nutrition history was unremarkable as was his family history.
Medications remained unchanged to 2015 (cf. previous section).
Despite continuous oral Mg substitution since 2015 (10 mmol
daily), blood analysis demonstrated persistent hypomagnesemia
(0.4 mmol/L), but serum potassium and calcium had normalized.
Blood gas analysis was normal, and calcium and magnesium
excretion in the 24-h urine (24 h) were very low with a
fractionated magnesium excretion rate of <1%. Based on these
results, the diagnosis of extrarenal magnesium wasting was
made and other differential diagnoses as Gitelman or Bartter
syndrome were excluded. Proton pump inhibitor (PPI)–induced
hypomagnesemia was considered as the most probable cause
and the medication was stopped. In the following weeks, Mg
normalized without improvement of clinical symptoms.
LITERATURE REVIEW
A literature review with regard to hypomagnesemia-induced
cerebellar syndromes was performed in PubMed, Google
scholar, and Google using among others the following terms:
“hypomagnesemia cerebellar,” “hypomagnesemia ataxia,” “low
magnesium cerebellar,” “hypomagnesemia brain oedema,”
“hypomagnesemia cerebral oedema,” “hypomagnesemia
cerebellar oedema,” and “hypomagnesemia Posterior Reversible
Leukoencephalopathy Syndrome.” We only included reports
that referred to clinical, laboratory, and MR-imaging data for
quality reasons. We identified 17 cases, so including our case, 18
cases contributed to this review. Table 1 summarizes the clinical,
Table 2 the brain MRI, and Table 3 the laboratory features of all
the cases.
DISCUSSION
HiCS seems to be a distinct disease entity due to the
remarkable similarities of clinical, laboratory, and MR-
tomographical features of the reported cases as summarized in
Tables 1–3.
In the majority of cases, there was a subacute onset
of predominately cerebellar symptoms that progressed over
time leading to a delayed hospitalization of usually days to
weeks. Symptoms included vertigo, nausea, vomiting, dysarthria,
oscillopsia, and walking impairments up to the inability to walk.
Additional symptoms were, among others, headache, cognitive
impairment, somnolence, and confusion, and 7/18 patients had
newly occurring hypomagnesemia-related seizures before or
during hospitalization (Table 1).
The neurological examination on admission predominately
yielded cerebellar symptoms including severe dysarthria,
cerebellar ataxia, and nystagmus. Different forms of nystagmus
were described; however, downbeat nystagmus as reported in
6/18 patients seems to be quite typical and a result of the frequent
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TABLE 2 | Brain MRI features of reported cases.
References Brain MRI at admission Follow-up brain MRI
Location Description (↑ ↓ ↔)
T
2
F
L
A
IR
D
W
I
A
D
C
T
1
G
d
Case report Bilateral cerebellar hemispheres ↑ ↑ ↑ ↑ ↓ – Improved, but sequelae
(3) Bilateral cerebellar hemispheres and vermis ↑ Improved, but sequelae
(4) Cerebellar nodulus with swelling ↑ ↑ Full resolution
(5) Bilateral cerebellar hemispheres, vermis ↑ Improved, but sequelae
(5) No acute abnormality
(5) Bilateral cerebellar hemispheres, cerebellar peduncles,
effacement of sulci
↑ ↔
(6) Left cerebellum ↑ Full resolution (4 weeks)
(7) Normal
(8) Bilateral cerebellar hemispheres (symmetrical) ↑ ↑ ↑ ↑ – Full resolution, MR-spectroscopy: residual
neuronal loss (3 months)
(9) Bilateral cerebellar hemispheres without significant mass
effect
↑ ↑ ↑ ↑ – Resolution of signal abnormality, volume
loss, MR-spectroscopy: neuronal loss
(10) Normal
(11) Cerebellar vermis (nodulus) ↑ ↔ – Full resolution
(12) Bilateral cerebellar hemispheres, cortical atrophy ↑ ↑ Improvement
(13) Bilateral cerebellar hemispheres ↑ ↑ Full resolution
(14) Bilateral cerebellar hemispheres (6 months before
admission), right cerebellar hemisphere on admission
↑ ↑
(15) Bilateral cerebellar vasogenic edema Significant improvement
(16) Normal
(17) Bilateral anterior lobe of the cerebellum, vermis (minor
alterations of mamillary bodies, periaqueductal area,
medial thalami region)
↑ ↑ ↑ Full resolution
Ref, References; MR, magnetic resonance; T2, T2-weighted images; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient;
T1, T1-weighted images; Gd, gadolinium enhancement (+, yes; –, no); ↑, hyperintense; ↓, hypointense; ↔, isointense/normal.
affection of the vermis and cerebellar nodulus as seen on MRI
(Table 2) (4–7, 11). In addition, periodic/intermittent nystagmus
might hint to HiCS as well being an overall rare neurological
presentation (4, 7).
MRI findings were remarkably similar across the reports
showing edema affecting the bilateral cerebellar hemispheres
(11/18 patients) and/or the cerebellar vermis/nodulus (5/18
patients). Only in one case, unilateral edema of the cerebellar
hemispheres was reported and 4/18 MRIs were normal despite
severe clinical symptoms (Table 2). Noteworthy, only one case
report described minor MR findings outside the cerebellum (17).
MRI abnormalities were all hyperintense on T2-weighted images
(T2W), fluid-attenuated inversion recovery (FLAIR) images,
diffusion-weighted images (DWI), and apparent diffusion
coefficient (ADC) images, and hypointense without gadolinium
(Gd) enhancement on T1-weighted images (T1W). However,
abnormalities were not always present in all sequences in the
individual patients with T2 and ADC images possibly being most
sensitive (Figure 1, Table 2).
Laboratory analysis showed severe hypomagnesemia almost
always below 0.2 mmol/L, and frequently secondary potassium
and calcium deficiency (Table 3).
Most common etiologies of hypomagnesemia were the usage
of PPIs in 12 of 18 patients, alcohol abuse (4/18 patients)
or intestinal malabsorption due to relevant gastrointestinal
diseases/gastric surgery (3/18 patients). This might explain the
predominately older population with a mean age of 58 years
(±14.2 SD) and a range from 32 to 80 years.
In the vast majority of cases, the diagnosis of
hypomagnesemia as was delayed by days to weeks, rarely
even months to years. Initial false diagnosis included
cerebellitis, paraneoplastic disorders, immune-mediated
syndromes, meningitis/encephalitis, Wernicke encephalopathy,
neurodegenerative process or toxic conditions leading to
extensive redundant diagnostic work-ups including laboratory
analysis with regard to paraneoplastic, infectious, and immune-
mediated disorders, CSF analysis, tumor screening using
imaging methods (CT, MRI, PET, sonography), urologic and
dermatologic examinations, coloscopy and gastroscopy as well as
stroke work-ups. Therefore, various redundant treatments were
performed including intravenous antibiotics/acyclovir, steroid
treatment, thiamine substitution, or stroke prophylaxis.
After the diagnosis of HiCS, Mg was mostly substituted
intravenously leading to a rapid clinical and MR-tomographical
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TABLE 3 | Laboratory features of reported cases.
References Magnesium
(NR: 0.7–1.05)
Potassium
(NR: 3.5–4.5)
Phosphate
(NR: 0.87–1.45)
Calcium
(NR: 2.20–2.55)
Case report
1 episode 0.16 2.9 1.25 1.65
2 episode 2.9 2.0
3 episode <0.1 3.2 0.83 1.76
(3) 0.19 2.4 0.59 Normal
(4) <0.08 1.73
(5) 0.22 3.3 Normal 1.77
(5) <0.2 1.27 2.24
(5) <0.2 2.8 1.19 1.99
(6) <0.1 Normal Normal
(7) 0.1 2.8
(8) <0.28 1.85
(9) 0.15 Normal Normal 1.59
(10) <0.1–0.38 3.4 1.95
(11) 0.28 2.3 0.68 1.63
(12) 0.4 3.1 1.03 2.48
(13) <0.12 3.2 1.25
(14) 0.16 Normal Normal 1.7
(15) 0.16 1.23 1.63
(16) 1.5 mEq/L
(17) <0.21 2.45 1.83
Values are in mmol/L if not otherwise stated; NR, normal range.
improvement in all cases. However, approximately half of
the patients had residual cerebellar symptoms affecting daily
life. Correspondingly, MRI showed residual signs of atrophy
and neuronal loss in approximately half of patients (Figure 1,
Table 2). Furthermore, recurrent disease course was reported in
6/18 patients due to initial misdiagnosis or insufficient treatment
(Table 1). Daily magnesium serum levels are highly variable
depending on dietary intake, actual renal function/excretion,
mobilization from bone/soft tissue, and endocrine factors
(i.e., impact of endocrine regulators as PTH or calcitonin).
Gastrointestinal magnesium wasting (i.e., caused by PPI
treatment) usually does not cause gastrointestinal symptoms.
Therefore, we hypothesize that our patient had a persistent severe
magnesium deficiency due to ongoing PPI treatment which
itself abolishes the effect of peroral repletion of magnesium
stores. This could be an explanation for recurrent HiCS in
our patient.
The delay in diagnosing HiCS and the recurrent disease
course in some patients might have contributed to a high
percentage of patients recovering with residual neurological
deficits. Importantly, the delay in diagnosis and treatment led,
among others, to seizures in 7/18 patients, arrythmia, cognitive
impairment and somnolence, and in one patient, to secondary
hydrocephalus due to cerebellar swelling with fourth ventricle
compression requiring external ventricular drain insertion (5).
These manifold complications further highlight the importance
of properly diagnosing and treating hypomagnesemia as early
as possible to avoid potentially life-threatening conditions.
Immediate IV Mg substitution seems to have a quick impact on
these conditions, and is therefore the most important therapeutic
action. The positive effect of the glucocorticoid pulse therapy in
our patient remains elusive because glucocorticoids do not lead to
higher Mg levels. A positive effect on the cerebellar edema could
however be postulated.
Because Mg is usually not part of the routine electrolyte
panel, the probability of underdiagnosing hypomagnesemia-
induced diseases is high, and physicians must be alert
to hypomagnesemia-related diseases and the severity of its
consequences (2). On the other hand, electrolyte changes must
be taken seriously, and reduced potassium and/or calcium values
could hint to severe hypomagnesemia (Table 3).
Depending on the pathophysiology, hypomagnesemia can
be classified into three main groups: (1) decreased intake
and/or redistribution, and (2) renal and (3) gastrointestinal
losses. Redistribution from extra- to intercellular compartment
occurs in refeeding syndrome or hungry bone syndrome
after parathyroidectomy. Renal Mg wasting can result from
various genetic defects leading to alterations in renal electrolyte
handling (i.e., Bartter or Gitelman syndrome) or is acquired
in the setting of medications (i.e., PPI, diuretics, cisplatin,
aminoglycoside antibiotics, cyclosporine), alcohol abuse, or
hypercalcemia. Hypomagnesemia due to gastrointestinal losses
arises in patients with diarrhea, vomiting, malabsorption
syndromes, or after bariatric surgery. PPIs rank among
the most prescribed medications worldwide and therapy
often lasts for months or even years. However, a clearly
underestimated side effect of long-term treatment with PPI
is promotion of gastrointestinal Mg wasting probably through
a direct inhibitory effect on active intestinal Mg absorption
mechanisms (18). This can lead to depletion of total body
Mg stores causing severe hypomagnesemia in the complete
absence of any gastrointestinal symptoms (19–21). Diagnosis
of the etiology of hypomagnesemia usually is straight forward.
Detailed assessment of the patient’s history focuses on dietary
habits, daily alcohol consumption, actual or past (i.e., st. p.
chemotherapy with platin-based substances) medications and
gastrointestinal symptoms. Laboratory evaluation includes, apart
from measurement of serum Mg and potassium, assessment
of calcium homeostasis (corrected serum calcium and PTH)
and blood gases in cases with suspected genetic causes of renal
magnesium loss (Bartter or Gitelman syndrome). Remarkably,
serum Mg represents <1% of total body Mg and therefore
correlates poorly with Mg stores and intracellular Mg content
(22). The most useful diagnostic step allowing discrimination
between renal and gastrointestinal Mg losses is measurement
of renal Mg excretion in the 24 h urine. Daily excretion
of more than 10 to 30mg or a fractional excretion of
Mg above 2% is an indicator of renal Mg wasting (23).
Treatment of hypomagnesemia involves cessation of triggers
(i.e., stopping/reducing medications) and supplementation of
magnesium by oral or parenteral route. Route of administration
and aggressiveness of correction depends on severity of the
clinical symptoms and signs.
In our opinion, HiCS seems to be a distinct disease entity that
can be differentiated from posterior reversible encephalopathy
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syndrome (PRES). In PRES, elevated blood pressure plays a
critical role in the majority of patients. In addition, PRES is
frequently observed in patients with (pre)eclampsia, sepsis, renal
diseases, or during treatment regimens with immunosuppressive
or cytotoxic agents (1). These conditions did not apply to the
majority of our patients with hypertension only reported in
2/18 patients on admission that was quickly reversible under
Mg substitution (24). PRES often presents with quantitative
and qualitative disorders of consciousness, headache, visual
disturbances (hemianopia, visual neglect, visual hallucinations,
cortical blindness) which were not the leading symptoms in our
case series except for seizures in 7/18 patients that are reported
in PRES in >70% of patients (24). Typical MRI features in
PRES are bilateral, frequently symmetric distributed lesions that
follow a parieto-occipital pattern in about 70%. In addition,
frontal and temporal lobe involvement and subcortical white
matter lesions are common (24, 25). Lesions in other areas
such as the cerebellum, brain stem, basal ganglia, or the spinal
cord are less common and show patchy and rounded foci
(26, 27). In contrast, lesion in our case series were exclusively
limited to the cerebellum showing a laminar and homogeneous
pattern except for one case reporting minor alterations outsight
the cerebellum that might be a result of concomitant diseases
(17). MR lesions of PRES and HiCS share the same pattern
being hyperintense in T2W, FLAIR, DWI, and ADC images
and iso- or hypointense without Gd enhancement on T1W
imaging resembling edema. In contrast, Gd-enhancing lesions
are described in about 20% of PRES. We cannot elute to
microhemorrhages that are described in up to 65% in PRES
because it was not reported in our case series (28). With
regard to pathophysiology, PRES and HiCS might share similar
mechanisms. In both diseases, endothelial dysfunction with
capillary leakage, blood–brain barrier disruption, and axonal
swelling leading to cerebral edema are often postulated. However,
the cause seems different predominantly being hypomagnesemia
in HiCS and hypertension in PRES (6, 24).
Differentiation to acute cerebellitis can be challenging
because of similar clinical presentations with subacute
cerebellar symptoms and similar pattern on MRI with
cerebellar hyperintensities in T2, FLAIR, DWI, and ADC
sequences in the majority of cases. However, in one case
series, fever and headache were present in 88 and 71% of
patients, Gd enhancement (cortical and leptomeningeal) in
78% of patients, median leukocyte count in the CSF was 104
(range 0–797), and an etiology (infectious, paraneoplastic,
medication induced) was found in 66% of cerebellitis cases
(29). These differences can help in differentiating cerebellitis
from HiCS.
Paraneoplastic cerebellar degeneration (PCD) can be
distinguished from HiCS by a slowly progressing non-relapsing
clinical course with cerebellar symptoms over weeks to months.
Additional neurologic presentations such as encephalomyelitis
or Lambert–Eaton syndrome may be present depending on the
cause of the disease (30). Identifying the underlying neoplasm
such as lung cancer, gynecologic cancer, breast cancer, and
lymphoma including testing for paraneoplastic antibodies such
as anti-Yo, anti-Tr, or antimetobotropic glutamate receptor
1 (mGluR1) is crucial in the diagnosis of PCD (30). MRI is
mostly normal helping to rule out differential diagnosis. Rarely,
there is contrast enhancement of the cerebellar folia, and in
the course of the disease, there is a cerebellar atrophy (31).
CSF analysis may reveal mild pleocytosis and a mildly elevated
protein, which despite the MRI, may help to distinguish PCD
from HiCS.
Overall, clinicians should be suspicious with regard to
HiCS in patients with subacute onset of predominately
cerebellar symptoms as well as seizures of unknown origin
in patients taking PPIs, having relevant gastrointestinal
diseases/gastric surgery or alcohol abuse. In the clinical
examination, downbeat and periodic/intermittent nystagmus
seems to be quite typical for HiCS. Mg concentration in
the blood and brain MRI helps to confirm the diagnosis in
most cases, the latter showing cerebellar edema as described
earlier and in Table 2 and Figure 1. In addition, differential
diagnosis such as PRES and cerebellitis as well as paraneoplastic,
infectious, or autoimmune diseases should be ruled out
(24–31).
CONCLUSION
HiCS seems to be a distinct disease entity because of
the remarkable similarities of clinical, laboratory, and MR-
tomographical features. It should be diagnosed and treated
early to avoid recurrent disease courses, residual symptoms,
and potentially life-threatening conditions such as seizures.
Physicians must be alert to hypomagnesemia-induced symptoms
including HiCS as Mg is usually not part of the routine
electrolyte panel.
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